IN2012DN02645A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02645A IN2012DN02645A IN2645DEN2012A IN2012DN02645A IN 2012DN02645 A IN2012DN02645 A IN 2012DN02645A IN 2645DEN2012 A IN2645DEN2012 A IN 2645DEN2012A IN 2012DN02645 A IN2012DN02645 A IN 2012DN02645A
- Authority
- IN
- India
- Prior art keywords
- adamts13
- formulations
- various diseases
- present
- conditions
- Prior art date
Links
- 102000043853 ADAMTS13 Human genes 0.000 abstract 4
- 108091005670 ADAMTS13 Proteins 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004064 dysfunction Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24435309P | 2009-09-21 | 2009-09-21 | |
| PCT/US2010/049723 WO2011035335A2 (en) | 2009-09-21 | 2010-09-21 | Stabilized liquid and lyophilized adamts13 formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02645A true IN2012DN02645A (en) | 2015-09-11 |
Family
ID=43598388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2645DEN2012 IN2012DN02645A (en) | 2009-09-21 | 2010-09-21 |
Country Status (21)
| Country | Link |
|---|---|
| US (9) | US8623352B2 (en) |
| EP (5) | EP4218797B9 (en) |
| JP (2) | JP5819303B2 (en) |
| KR (6) | KR20250008986A (en) |
| CN (2) | CN104224705B (en) |
| AU (1) | AU2010295299B2 (en) |
| BR (1) | BR112012006283B1 (en) |
| CA (1) | CA2774556A1 (en) |
| DK (4) | DK2480198T3 (en) |
| EA (1) | EA024267B1 (en) |
| ES (4) | ES3001509T3 (en) |
| FI (2) | FI3834841T3 (en) |
| FR (1) | FR24C1049I2 (en) |
| HR (1) | HRP20160295T1 (en) |
| HU (1) | HUE028688T2 (en) |
| IN (1) | IN2012DN02645A (en) |
| MX (3) | MX362382B (en) |
| NZ (1) | NZ598839A (en) |
| PL (4) | PL2480198T3 (en) |
| PT (2) | PT4218797T (en) |
| WO (1) | WO2011035335A2 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3388529A1 (en) | 2008-12-05 | 2018-10-17 | Baxalta GmbH | Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof |
| AU2010295299B2 (en) | 2009-09-21 | 2015-12-24 | Takeda Pharmaceutical Company Limited | Stabilized liquid and lyophilized ADAMTS13 formulations |
| DK2814514T3 (en) * | 2012-02-16 | 2017-12-18 | Atyr Pharma Inc | Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases |
| CN103566362B (en) * | 2012-07-21 | 2015-07-29 | 复旦大学 | Restructuring ADAMTS13 is preparing the purposes in cerebral hemorrhage medicine |
| WO2014075033A2 (en) | 2012-11-09 | 2014-05-15 | Puget Sound Blood Center | Protein stabilizing factors |
| AU2013203062C1 (en) * | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
| ES2847383T3 (en) | 2013-03-15 | 2021-08-03 | Atyr Pharma Inc | Fc-histidyl-tRNA synthetase conjugates |
| AU2015280480A1 (en) * | 2014-06-26 | 2017-01-05 | Amgen Inc. | Protein formulations |
| GB201510870D0 (en) * | 2015-05-26 | 2015-08-05 | Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh | Treatment of infarction |
| ES2983978T3 (en) | 2016-01-08 | 2024-10-28 | Univ Kyoto | Medicine comprising ADAMTS13 as the main ingredient |
| KR20230079461A (en) | 2016-08-04 | 2023-06-07 | 다케다 파머수티컬 컴패니 리미티드 | Use of adamts13 for treating, ameliorating and/or preventing acute lung injury and/or acute respiratory distress syndrome |
| ES2981519T3 (en) | 2016-11-04 | 2024-10-09 | Takeda Pharmaceuticals Co | Adeno-associated virus formulations |
| EP3612215B1 (en) | 2017-04-20 | 2024-08-28 | aTyr Pharma, Inc. | Compositions for treating lung inflammation |
| UA125971C2 (en) * | 2017-07-25 | 2022-07-20 | Джянгсу Хенгруй Медісін Ко., Лтд. | Il-15 protein complex pharmaceutical composition and uses thereof |
| MX2020013953A (en) * | 2018-07-11 | 2021-03-09 | Takeda Pharmaceuticals Co | Aav compositions. |
| EP4037704B1 (en) | 2019-10-04 | 2025-12-03 | The Children's Medical Center Corporation | Adamts13 treatment to enhance graft survival |
| WO2021198781A2 (en) | 2020-04-02 | 2021-10-07 | Takeda Pharmaceutical Company Limited | Adamts13 variant, compositions, and uses thereof |
| JP2023526546A (en) | 2020-05-22 | 2023-06-21 | 武田薬品工業株式会社 | ADAMTS13 compositions and methods for treatment and diagnosis of complications of coronavirus disease |
| US20230295597A1 (en) * | 2020-08-13 | 2023-09-21 | Hadasit Medical Research Services & Development Limited | A disintegrin and metalloproteinase with a thrombospondin type i motif, member 13 (adamts-13) mutants, compositions and therapeutic methods thereof |
| CA3244889A1 (en) | 2022-03-08 | 2023-09-14 | Equashield Medical Ltd | Fluid transfer station in a robotic pharmaceutical preparation system |
| KR20240112755A (en) * | 2023-01-11 | 2024-07-19 | 주식회사 녹십자 | A Novel Liquid Formulation for Preventing or Treating Thrombotic Disease |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
| AT407255B (en) | 1997-06-20 | 2001-02-26 | Immuno Ag | RECOMBINANT CELL CLONE WITH INCREASED STABILITY IN SERUM- AND PROTEIN-FREE MEDIUM AND METHOD FOR OBTAINING THE STABLE CELL CLONE |
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| DK1820516T3 (en) | 1999-02-22 | 2013-10-28 | Univ Connecticut | New albumin-free factor VIII preparations |
| JP2001227510A (en) | 2000-02-15 | 2001-08-24 | Tomoe Tech Res Co | Double-acting pneumatic actuator |
| JP3783507B2 (en) | 2000-02-16 | 2006-06-07 | 日本精工株式会社 | Machining method of toroidal type continuously variable transmission disk |
| US6926894B2 (en) | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
| JP2003284570A (en) | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | VON WILLEBRAND FACTOR (vWF) BREAKING ENZYME |
| US7037658B2 (en) * | 2001-08-16 | 2006-05-02 | Regents Of University Of Michigan | Methods and compositions for detecting variant ADAMTS13 genes |
| ITPR20010055A1 (en) | 2001-08-31 | 2003-03-03 | Vetroarredo Spa | PROCEDURE AND PLANT FOR THE CREATION OF GLASS BRICKS. |
| KR100472006B1 (en) | 2002-10-09 | 2005-03-10 | 동부아남반도체 주식회사 | Method for manufacturing MOS transistor |
| JP5112692B2 (en) * | 2003-07-07 | 2013-01-09 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Method and system for detecting von Willebrand factor (VWF) multimers |
| GB0404693D0 (en) * | 2004-03-02 | 2004-04-07 | Univ London | Pharmaceutical preparations for the treatment of ocular surface and other disorders |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| PL1902141T3 (en) | 2005-06-17 | 2012-12-31 | Baxalta Inc | Adamts13-comprising compositions having thrombolytic activity |
| JP4880997B2 (en) * | 2005-12-28 | 2012-02-22 | アルフレッサファーマ株式会社 | Method for stabilizing ADAMTS13 |
| PL3121266T3 (en) | 2006-01-04 | 2020-07-13 | Baxalta Incorporated | Oligopeptide-free cell culture media |
| AU2010295299B2 (en) * | 2009-09-21 | 2015-12-24 | Takeda Pharmaceutical Company Limited | Stabilized liquid and lyophilized ADAMTS13 formulations |
| US8823352B2 (en) | 2011-07-11 | 2014-09-02 | Linear Technology Corporation | Switching power supply having separate AC and DC current sensing paths |
-
2010
- 2010-09-21 AU AU2010295299A patent/AU2010295299B2/en active Active
- 2010-09-21 MX MX2016005314A patent/MX362382B/en unknown
- 2010-09-21 HU HUE10759786A patent/HUE028688T2/en unknown
- 2010-09-21 EP EP23172759.5A patent/EP4218797B9/en active Active
- 2010-09-21 PL PL10759786.6T patent/PL2480198T3/en unknown
- 2010-09-21 PL PL20211228.0T patent/PL3834841T3/en unknown
- 2010-09-21 FI FIEP20211228.0T patent/FI3834841T3/en active
- 2010-09-21 NZ NZ598839A patent/NZ598839A/en unknown
- 2010-09-21 WO PCT/US2010/049723 patent/WO2011035335A2/en not_active Ceased
- 2010-09-21 DK DK10759786.6T patent/DK2480198T3/en active
- 2010-09-21 ES ES23172759T patent/ES3001509T3/en active Active
- 2010-09-21 KR KR1020247043292A patent/KR20250008986A/en active Pending
- 2010-09-21 EA EA201200519A patent/EA024267B1/en not_active IP Right Cessation
- 2010-09-21 KR KR1020217013486A patent/KR20210054598A/en not_active Ceased
- 2010-09-21 BR BR112012006283-2A patent/BR112012006283B1/en active IP Right Grant
- 2010-09-21 IN IN2645DEN2012 patent/IN2012DN02645A/en unknown
- 2010-09-21 US US12/887,424 patent/US8623352B2/en active Active
- 2010-09-21 DK DK15203085.4T patent/DK3167897T3/en active
- 2010-09-21 EP EP24192531.2A patent/EP4467160A3/en active Pending
- 2010-09-21 EP EP15203085.4A patent/EP3167897B1/en active Active
- 2010-09-21 MX MX2012003414A patent/MX339205B/en active IP Right Grant
- 2010-09-21 KR KR1020227034508A patent/KR20220139456A/en not_active Ceased
- 2010-09-21 FI FIEP23172759.5T patent/FI4218797T3/en active
- 2010-09-21 CN CN201410452647.8A patent/CN104224705B/en active Active
- 2010-09-21 PT PT231727595T patent/PT4218797T/en unknown
- 2010-09-21 ES ES15203085T patent/ES2865250T3/en active Active
- 2010-09-21 EP EP10759786.6A patent/EP2480198B9/en active Active
- 2010-09-21 ES ES10759786.6T patent/ES2579906T3/en active Active
- 2010-09-21 KR KR1020197035791A patent/KR20190137954A/en not_active Ceased
- 2010-09-21 CA CA2774556A patent/CA2774556A1/en not_active Abandoned
- 2010-09-21 HR HRP20160295TT patent/HRP20160295T1/en unknown
- 2010-09-21 PL PL23172759.5T patent/PL4218797T3/en unknown
- 2010-09-21 DK DK23172759.5T patent/DK4218797T5/en active
- 2010-09-21 KR KR1020187023806A patent/KR20180095738A/en not_active Ceased
- 2010-09-21 ES ES20211228T patent/ES2948612T3/en active Active
- 2010-09-21 KR KR1020127009803A patent/KR101891646B1/en active Active
- 2010-09-21 PT PT202112280T patent/PT3834841T/en unknown
- 2010-09-21 PL PL15203085T patent/PL3167897T3/en unknown
- 2010-09-21 EP EP20211228.0A patent/EP3834841B1/en active Active
- 2010-09-21 CN CN201080046707.6A patent/CN102573792B/en active Active
- 2010-09-21 DK DK20211228.0T patent/DK3834841T3/en active
- 2010-09-21 JP JP2012529982A patent/JP5819303B2/en active Active
-
2012
- 2012-03-21 MX MX2019000547A patent/MX2019000547A/en unknown
-
2013
- 2013-11-22 US US14/088,169 patent/US9351935B2/en active Active
-
2014
- 2014-12-24 JP JP2014259954A patent/JP2015063556A/en active Pending
-
2016
- 2016-05-03 US US15/145,755 patent/US9572778B2/en active Active
-
2017
- 2017-01-06 US US15/400,526 patent/US9937244B2/en active Active
-
2018
- 2018-02-28 US US15/908,213 patent/US10238720B2/en active Active
-
2019
- 2019-02-14 US US16/275,690 patent/US10758599B2/en active Active
-
2020
- 2020-07-21 US US16/934,100 patent/US11564979B2/en active Active
-
2022
- 2022-12-23 US US18/146,212 patent/US12178861B2/en active Active
-
2024
- 2024-11-19 US US18/952,409 patent/US20250099559A1/en active Pending
- 2024-12-10 FR FR24C1049C patent/FR24C1049I2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02645A (en) | ||
| UA108198C2 (en) | Substituted 2-acetamido-5-aryl-l, 2,4-triazolones and their use | |
| MX2013006040A (en) | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis. | |
| UA115983C2 (en) | Dna-pk inhibitors | |
| TN2012000126A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| HK1203356A1 (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
| IN2012DN02737A (en) | ||
| WO2012088266A3 (en) | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 | |
| IN2012DN02177A (en) | ||
| IN2012DN00754A (en) | ||
| AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
| MD20150035A2 (en) | Bruton's tyrosine kinase inhibitors | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| MX2009009491A (en) | Compounds and compositions as modulators of gpr119 activity. | |
| MX2013004061A (en) | Cyclosporin analogs. | |
| MX2012004078A (en) | Compounds and compositions as modulators of gpr119 activity. | |
| DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
| MX2011013032A (en) | Inhibitors of phosphatidylinositol 3-kinase. | |
| MY164998A (en) | Isoquinolinone derivatives as nk3 antagonists | |
| MX2013004062A (en) | Cyclosporin analogs. | |
| MX2011008645A (en) | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase. | |
| WO2014100857A8 (en) | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy | |
| EP2597949A4 (en) | Sub-micron compositions | |
| WO2011091154A3 (en) | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth |